Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background/aims: Voretigene neparvovec (VN) is the first and only subretinal gene therapy approved by the Food and Drug Administration and European Medicines Agency. Real-world application has started in 2018 in patients with vision impairment due to biallelic retinal pigment epithelium (RPE)65 mutation-associated inherited retinal degenerations. Herein, we evaluated the development of retinal atrophy within in a single-centre patient cohort treated with VN. Methods: 13 eyes of eight patients treated with VN were retrospectively analysed for areas of retinal atrophy over a period of 6–24 months following surgery. Ultrawide field images were used to measure the area of atrophy. Fundus autofluorescence imaging is presented as an instrument for early detection of signs of retinal atrophy in these patients. Results: Atrophic changes beyond the retinotomy site were observed in all eyes. Areas of atrophy developed within the area of detachment (bleb) in all eight patients and outside the bleb in three patients. Changes in autofluorescence preceded the development of retinal atrophy and were already evident 2 weeks after surgery in the majority of patients. The areas of atrophy increase with time and progression continued over year 1. Functional outcomes remained stable (VA, FST, visual field). Conclusion: Subretinal injection of VN can lead to RPE atrophy with consequent photoreceptor loss in and outside of the bleb area. Fundus autofluorescence is an important tool to monitor atrophic changes in patients after gene therapy. Interestingly, while areas of atrophy also included central areas, the functional benefits of the treatment did not appear to be affected and remained stable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461
Fischer, M. D., Michalakis, S., Wilhelm, B., Zobor, D., Muehlfriedel, R., Kohl, S., Weisschuh, N., Ochakovski, G. A., Klein, R., Schoen, C., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.1032 · Cited by 177
Self-citationSeitz, I. P., Michalakis, S., Wilhelm, B., Reichel, F. F., Ochakovski, G. A., Zrenner, E., Ueffing, M., Biel, M., Wissinger, B., Bartz-Schmidt, K. U., et al. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22473 · Cited by 108
Self-citationFischer, M. D., Ochakovski, G. A., Beier, B., Seitz, I. P., Vaheb, Y., Kortuem, C., Reichel, F. F. L., Kuehlewein, L., Kahle, N. A., Peters, T., et al. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.3278 · Cited by 92
Self-citationHumoral immune response after intravitreal but not after subretinal AAV8 in primates and patients
Reichel, F. F., Peters, T., Wilhelm, B., Biel, M., Ueffing, M., Wissinger, B., Bartz-Schmidt, K. U., Klein, R., Michalakis, S., Fischer, M. D., et al. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22494 · Cited by 86
Self-citationChanges in Retinal Sensitivity after Gene Therapy in Choroideremia
Fischer, M. D., Ochakovski, G. A., Beier, B., Seitz, I. P., Vaheb, Y., Kortuem, C., Reichel, F. F. L., Kuehlewein, L., Kahle, N. A., Peters, T., et al. (2020) · Retina · doi:10.1097/iae.0000000000002360 · Cited by 66
Self-citationEvaluation of an optimized injection system for retinal gene therapy in human patients
Fischer, M. D., Hickey, D. G., Singh, M. S., & MacLaren, R. E. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.086 · Cited by 61
Self-citationOchakovski, G. A., Peters, T., Michalakis, S., Wilhelm, B., Wissinger, B., Biel, M., Bartz-Schmidt, K. U., Fischer, M. D., & for the RD-CURE Consortium (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22402 · Cited by 38
Self-citation
Cited by
Fischer, M. D., Simonelli, F., Sahni, J., Holz, F. G., Maier, R., Fasser, C., Suhner, A., Stiehl, D. P., Chen, B., Audo, I., et al. (2024) · Biomolecules · doi:10.3390/biom14010122 · Cited by 70
Self-citationTherapy with voretigene neparvovec. How to measure success?
Stingl, K., Kempf, M., Jung, R., Kortüm, F., Righetti, G., Reith, M., Dimopoulos, S., Ott, S., Kohl, S., & Stingl, K. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101115 · Cited by 48
Self-citationSyndromic retinitis pigmentosa.
Karuntu, J. S., Almushattat, H., Nguyen, X.-T.-A., Plomp, A. S., Wanders, R. J. A., Hoyng, C. B., van Schooneveld, M. J., Schalij-Delfos, N. E., Brands, M. M., Leroy, B. P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101324 · Cited by 39
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“Ellipsoid zone disruption a few weeks after gene therapy has been observed by OCT prior to the onset of CRA in some patients (Reichel et al., 2022b).”
Self-citationCarvalho, C., Lemos, L., Antas, P., & Seabra, M. C. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2023.1270561 · Cited by 21
Metadata
- Authors
- Reichel, F. F., Seitz, I., Wozar, F., Dimopoulos, S., Jung, R., Kempf, M., Kohl, S., Kortüm, F. C., Ott, S., Pohl, L., Stingl, K., Bartz-Schmidt, K. U., Stingl, K., & Fischer, M. D.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2022-05-24
- Volume
- 107
- Issue
- 9
- Pages
- 1331-1335
- ISSN
- 0007-1161 (ISSN-L)
- 1468-2079
- OpenAlex
- W4281382958
- Cited by
- 79
- References
- 8
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec. https://app.cochat.ai/papers/10.1136/bjophthalmol-2021-321023
- The paper
- Reichel, F. F., Seitz, I., Wozar, F., Dimopoulos, S., Jung, R., Kempf, M., Kohl, S., Kortüm, F. C., Ott, S., Pohl, L., Stingl, K., Bartz-Schmidt, K. U., Stingl, K., & Fischer, M. D. (2023). Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2021-321023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.